Claims for Patent: 10,376,595

Summary for Patent: 10,376,595

Title:	Treatment of inflammatory diseases with inhibitors of C5a activity
Abstract:	The present invention relates to inhibitors of C5a activity and their use in the treatment of cutaneous, neutrophilic, inflammatory diseases in a subject.
Inventor(s):	Guo; Renfeng (Ann Arbor, MI), Riedemann; Niels C. (Jena, DE)
Assignee:	InflaRx GmbH (Jena, DE)
Application Number:	16/007,340
Patent Claims:	1. A method of treating Hidradenitis suppurativa (HS) or a HS-related disease in a subject, the method comprising: administering to the subject in need thereof an effective amount of an agent that inhibits C5a activity in the subject, wherein the HS-related disease is selected from the group consisting of Pyoderma gangrenosum (PG); PASH (PG, acne and Hidradenitis suppurativa); and PAPASH (Pyogenic arthritis, acne, PG and Hidradenitis suppurativa). 2. The method of claim 1, wherein the agent inhibits C5a activity by one or more of: lowering the concentration of C5; inhibiting cleavage of C5 into C5a and C5b; lowering the concentration of C5a; inhibiting binding between C5a and a C5a receptor; lowering the concentration of a C5a receptor; or inhibiting the activity of a C5a receptor. 3. The method of claim 1, wherein the agent inhibits C5a activity, reduces expression of C5 protein or C5a receptor protein. 4. The method of claim 1, wherein the C5a receptor is selected from the group consisting of C5aR and C5L2. 5. The method of claim 1, wherein the agent that inhibits C5a activity is ALN-CC5 or Avacopan. 6. The method of claim 1, wherein the compound is administered at a dose of 800 mg once per week or at a dose of 800 mg twice per week. 7. A method of inhibiting the interaction of a C5a receptor with a C5a receptor ligand to treat Hidradenitis suppurativa (HS) or a HS-related disease in a subject, the method comprising administering to the subject an agent that specifically binds to C5, to the C5a receptor, or to the C5a receptor ligand, thereby inhibiting the interaction of the C5a receptor with the C5a receptor ligand and treating the disease, wherein the HS-related disease is selected from the group consisting of Pyoderma gangrenosum (PG); PASH (PG, acne and Hidradenitis suppurativa); and PAPASH (Pyogenic arthritis, acne, PG and Hidradenitis suppurativa). 8. The method of claim 7, wherein the agent is selected from the group consisting of an antibody or an antigen-binding fragment thereof, an antibody-like protein, an inhibitory variant of C5a, an inhibitory variant of a C5a receptor, a protein acting on the complement pathway, a peptide, a small molecule, an oligonucleotide and an aptamer. 9. The method of claim 5, wherein the agent that inhibits C5a activity is Avacopan. 10. A method of treating Hidradenitis suppurativa (HS) or an HS-related disease in a subject, the method comprising: administering to the subject in need thereof an agent that inhibits C5a activity in the subject in an effective amount to treat HS or the HS-related disease, wherein the agent is selected from the group consisting of Avacopan, IFX-1, INab708, MEDI-7814, ALXN-1007, Eculizumab, ALXN1210, LFG316, ALXN5500, Coversin, RA101495, NOX-D21, Zimura, and ALN-CCS; and wherein the HS-related disease is selected from the group consisting of Pyoderma gangrenosum (PG); PASH (PG, acne and Hidradenitis suppurativa); and PAPASH (Pyogenic arthritis, acne, PG and Hidradenitis suppurativa). 11. A method of treating Hidradenitis suppurativa (HS) in a subject, the method comprising: administering to the subject in need thereof an agent that inhibits C5a activity in the subject in an effective amount to treat HS, wherein the agent is selected from the group consisting of Avacopan, IFX-1, INab708, MEDI-7814, ALXN-1007, Eculizumab, ALXN1210, LFG316, ALXN5500, Coversin, RA101495, NOX-D21, Zimura, and ALN-CCS. 12. The method of claim 10, wherein the subject has Hidradenitis suppurativa (HS) and the agent that inhibits C5a activity in the subject is Avacopan or IFX-1. 13. The method of claim 11, wherein the agent that inhibits C5a activity in the subject is Avacopan or IFX-1. 14. The method of claim 10, wherein the subject has Hidradenitis suppurativa (HS) and the agent that inhibits C5a activity in the subject is Avacopan. 15. The method of claim 11, wherein the agent that inhibits C5a activity in the subject is Avacopan. 16. The method of claim 10, wherein the subject has Hidradenitis suppurativa (HS) and the agent that inhibits C5a activity in the subject is IFX-1. 17. The method of claim 11, wherein the agent that inhibits C5a activity in the subject is IFX-1. 18. A method of treating Hidradenitis suppurativa (HS) or a HS-related disease in a subject, the method comprising: administering to a subject in need thereof an effective amount of Avacopan to treat HS or the HS-related disease, wherein the HS-related disease is selected from the group consisting of Pyoderma gangrenosum (PG); PASH (PG, acne and Hidradenitis suppurativa); and PAPASH (Pyogenic arthritis, acne, PG and Hidradenitis suppurativa). 19. A method of treating Hidradenitis suppurativa (HS) or a HS-related disease in a subject, the method comprising: administering to a subject in need thereof an effective amount of IFX-1 antibody, or an antigen-binding fragment thereof, to treat HS or the HS-related disease, wherein the HS-related disease is selected from the group consisting of Pyoderma gangrenosum (PG); PASH (PG, acne and Hidradenitis suppurativa); and PAPASH (Pyogenic arthritis, acne, PG and Hidradenitis suppurativa).

Details for Patent 10,376,595

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Alexion Pharmaceuticals, Inc.	SOLIRIS	eculizumab	Injection	125166	03/16/2007		2037-04-03